Reviva Financial Statements From 2010 to 2025

RVPH Stock  USD 1.41  0.05  3.42%   
Reviva Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Reviva Pharmaceuticals Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Reviva Pharmaceuticals financial statements helps investors assess Reviva Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Reviva Pharmaceuticals' valuation are summarized below:
Market Capitalization
65.7 M
Earnings Share
(1.08)
We have found one hundred four available trending fundamental ratios for Reviva Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Reviva Pharmaceuticals recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Reviva Pharmaceuticals' current Market Cap is estimated to increase to about 115.8 M. The Reviva Pharmaceuticals' current Enterprise Value is estimated to increase to about 93.7 M
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 156.3 K, Tax Provision of 10 K or Net Interest Income of 602.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 20.25. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Reviva Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities20.7 M19.8 M8.1 M
Slightly volatile
Accounts Payable4.6 M4.4 M1.2 M
Slightly volatile
Other Assets467.6 K464.4 K217.2 K
Slightly volatile
Total Current Assets15.2 M27.3 M7.9 M
Slightly volatile
Common Stock3.4 K3.2 K1.2 K
Slightly volatile
Property Plant Equipment731532959
Slightly volatile
Total Assets18.2 M27.3 MM
Slightly volatile
Short and Long Term Debt TotalM3.4 M3.7 M
Slightly volatile
Current Deferred Revenue2.2 M2.5 M2.7 M
Slightly volatile
Cash17.7 M26.9 M7.8 M
Slightly volatile
Non Currrent Assets Other1.5 K1.6 K1.8 K
Slightly volatile
Cash And Short Term Investments17.7 M26.9 M7.8 M
Slightly volatile
Common Stock Total Equity8481.1 K736
Slightly volatile
Common Stock Shares Outstanding14.1 M27.4 M8.1 M
Slightly volatile
Short Term Investments52.2 M58.7 M64 M
Slightly volatile
Liabilities And Stockholders Equity18.2 M27.3 MM
Slightly volatile
Non Current Liabilities Total1.4 M726 K2.9 M
Slightly volatile
Other Stockholder Equity105.2 M161.1 M87.7 M
Slightly volatile
Total Liabilities21.7 M20.7 M8.7 M
Slightly volatile
Property Plant And Equipment Gross50.4 K48 K16.9 K
Slightly volatile
Short and Long Term DebtM3.4 M3.7 M
Slightly volatile
Capital Stock2.4 K2.5 K18.2 M
Slightly volatile
Short Term DebtM3.4 M3.7 M
Slightly volatile
Other Liabilities774.4 K510.7 K1.5 M
Slightly volatile
Other Current Assets504.5 K299.6 K251.4 K
Slightly volatile

Reviva Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision10 K19.5 K5.1 K
Slightly volatile
Interest Income602.5 K573.8 K134.3 K
Slightly volatile
Depreciation And Amortization212.7 K223.9 K157.9 K
Slightly volatile
Selling General Administrative9.8 T9.3 T1.7 T
Slightly volatile
Other Operating Expenses47.7 M45.4 M10.8 M
Slightly volatile
Research Development37.9 T36.1 T6.6 T
Slightly volatile
Total Operating Expenses47.7 T45.4 T8.3 T
Slightly volatile
Reconciled Depreciation91.4996.3472
Slightly volatile
Cost Of Revenue579.8 K652.3 K711.2 K
Slightly volatile

Reviva Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings3.8 M3.6 M1.3 M
Slightly volatile
Other Cashflows From Financing Activities3.7 M5.1 MM
Slightly volatile
Depreciation91.4996.3681
Slightly volatile
Total Cash From Financing Activities40.1 M38.1 M10.3 M
Slightly volatile
End Period Cash Flow14.8 M26.9 M7.7 M
Slightly volatile
Begin Period Cash Flow12.6 M21.3 M5.8 M
Slightly volatile
Issuance Of Capital Stock18.5 M31.6 M7.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables3.5 M3.3 MM
Slightly volatile
Payables Turnover0.580.650.706
Slightly volatile
Cash Per Share1.071.1315.2798
Slightly volatile
Days Payables Outstanding406457498
Slightly volatile
Income Quality0.620.650.6877
Pretty Stable
Current Ratio1.511.591.7237
Slightly volatile
Graham Number2.8 K2.7 K535
Slightly volatile
Graham Net Net0.250.2613.53
Slightly volatile
Interest Debt Per Share0.01020.01080.9874
Slightly volatile
Debt To Assets1.2 K1.3 K1.4 K
Slightly volatile
Days Of Payables Outstanding406457498
Slightly volatile
Ebt Per Ebit0.00.01.1947
Slightly volatile
Quick Ratio1.511.591.7237
Slightly volatile
Net Income Per E B T945.4 K900.4 K177.9 K
Slightly volatile
Cash Ratio1.491.561.6695
Slightly volatile
Debt Ratio1.2 K1.3 K1.4 K
Slightly volatile

Reviva Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap115.8 M110.3 M49.6 M
Slightly volatile
Enterprise Value93.7 M89.3 M44.2 M
Slightly volatile

Reviva Fundamental Market Drivers

Cash And Short Term Investments23.4 M

Reviva Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Reviva Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Reviva Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.2 M
Cost Of Revenue652.3 K579.8 K

Currently Active Assets on Macroaxis

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.08)
Return On Assets
(3.28)
Return On Equity
(17.95)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.